Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. (symbol: PSNL) is a leading genome-scale diagnostics company dedicated to advancing the field of genome-guided medicine. The company's mission is to extract the most accurate genetic data from each sample and draw reliable, medically-focused conclusions. Personalis leverages cutting-edge whole genome and exome sequencing techniques, conducted in their state-of-the-art laboratory, to provide comprehensive insights.
Personalis offers a range of products and services designed to support academic, pharmaceutical, and biotech researchers. Their flagship products include ImmunoID NeXT, NeXT Personal, and NeXT Dx Test, which cater to diverse needs including personalized cancer vaccines and next-generation cancer immunotherapies. Additionally, their solutions serve those engaged in large case-control and family-based genome studies of complex or Mendelian diseases, pharmacogenomics, and cancer research.
Their proprietary databases, advanced human reference sequences, and sophisticated algorithms ensure accurate and comprehensive end-to-end human genome sequencing and analysis. Personalis' commitment to quality and innovation positions them as a critical player in the evolving landscape of genomic medicine.
Recent achievements include partnerships with key pharmaceutical companies to enhance the development of personalized cancer treatments. The company continues to innovate and expand its service offerings, ensuring researchers and clinicians have access to the most advanced tools for genomic analysis.
For those seeking the latest updates and relevant information on Personalis, Inc., StockTitan provides a comprehensive list of news and developments, ensuring investors and stakeholders stay informed on this pioneering company's performance and advancements.
Personalis, Inc. (Nasdaq: PSNL), a leader in cancer genomics, announced its participation in the 23rd Annual Needham Virtual Growth Conference on January 13, 2021, at 2:45 p.m. Eastern Time. The company specializes in population sequencing and oncology, offering advanced molecular data to improve cancer treatment. Its ImmunoID NeXT Platform analyzes approximately 20,000 human genes and immune responses from a single tissue sample, supporting biopharmaceutical development. Personalis is recognized for its extensive sequencing operations and is the exclusive sequencing provider for the VA MVP.
Personalis, Inc. (Nasdaq: PSNL) has launched its innovative Neoantigen Presentation Score (NEOPS), which enhances cancer therapy predictions by integrating tumor neoantigen analysis with immune evasion mechanisms. NEOPS leverages the SHERPA™ tool and the Personalis NeXT Platform™ to improve patient stratification for immunotherapy responses. Data from an AACR meeting showcased NEOPS's superior predictive capabilities over traditional metrics like tumor mutational burden in late-stage melanoma patients. This development positions NEOPS as a vital tool for future clinical trials.
Personalis, Inc. (Nasdaq: PSNL) has launched its proprietary SHERPA tool, a machine learning algorithm designed for identifying cancer neoantigens. Integrated into the Personalis® NeXT Platform™, SHERPA is set to enhance the development of novel neoantigen-based diagnostic biomarkers, such as the Neoantigen Presentation Score (NEOPS™). Data from the SITC Annual Meeting indicates SHERPA exceeds traditional neoantigen prediction methods. The tool is also being utilized by Sarepta Therapeutics for precision genetic therapeutics, highlighting its versatility beyond oncology.
Personalis, Inc. (Nasdaq: PSNL) announced its upcoming presentation of clinical data for the NeXT DxTM test at the virtual AMP Annual Meeting from Nov 16-20, 2020. The poster, titled “An exome and transcriptome based NeXT DxTM test enables therapy selection for cancer patients,” will take place on Nov 17th between 1-2pm EST. The NeXT Dx test provides a diagnostic report on genomic alterations in 247 cancer-related genes and offers therapy recommendations, clinical trial matching, and biomarker results.
Personalis, Inc. (Nasdaq: PSNL) will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting online from November 11-14. The company will present its ImmunoID NeXT™ platform, which enables comprehensive analysis of tumors and their immune microenvironment from a single sample. Key poster presentations include topics like tumor circulating cell-free DNA profiling and precision neoantigen discovery. Additionally, an industry symposium on maximizing immunotherapy biomarker discovery will take place on November 12.
Personalis, Inc. (Nasdaq: PSNL), a leader in cancer genomics, announced its participation in upcoming investor conferences. The company will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on November 10, 2020, at 4:15 p.m. ET. Additionally, it will participate in the Oppenheimer Fall MedTech Summit on November 12, 2020. Personalis focuses on providing comprehensive molecular data through its ImmunoID NeXT Platform, aimed at enhancing cancer therapy development. The firm is also involved in the VA Million Veterans Program to sequence veteran genomes.
Personalis, Inc. (Nasdaq: PSNL), a leader in cancer genomics, will release its Q3 2020 financial results on November 5, 2020, post-market. A conference call and webcast will be held at 2:00 PM PT / 5:00 PM ET to discuss these results and recent developments. The company specializes in advanced genomic solutions for cancer, utilizing its ImmunoID NeXT Platform to analyze 20,000 human genes and immune responses from patient samples. Personalis is also partnering with the VA Million Veterans Program to sequence over two million veteran genomes.
Personalis, Inc. (Nasdaq: PSNL) announced its participation at the Immuno Series US Virtual meeting on October 15-16, 2020. The company will present on maximizing biomarker discovery using its ImmunoID NeXT™ platform. Dr. Kedar Hastak will address challenges in immuno-oncology research and how enhanced biomarker analysis can inform combinatorial immunotherapy. The platform integrates DNA and RNA sequencing for a comprehensive cancer characterization, showcasing case studies that reveal insights into tumor biology and treatment efficacy.
Personalis, Inc. (Nasdaq: PSNL) announced its participation in the online conference IO Combinations 360˚ on October 1-2, 2020. Dr. Travis Yates will present on the "Comprehensive immunogenomics to enable composite biomarkers for immunotherapy response using a sample sparing approach." The presentation will cover the innovative ImmunoID NeXT platform, focusing on its benefits in immuno-oncology research, including case studies from metastatic melanoma patients. Personalis aims to enhance cancer therapy development by providing detailed genomic data about patients’ cancers and immune responses.
FAQ
What is the current stock price of Personalis (PSNL)?
What is the market cap of Personalis (PSNL)?
What does Personalis, Inc. specialize in?
What are Personalis' main products?
Who can benefit from Personalis' services?
What technologies does Personalis use?
What is the mission of Personalis, Inc.?
How does Personalis support cancer research?
What recent achievements has Personalis made?
What sets Personalis apart from other genomic companies?
Why is genome sequencing important in medical research?
How can I stay updated on Personalis' latest news?
